Precision 'Radium' Therapy Eases Pain, Extends Life for Prostate Cancer Patients with Bone Metastasis

For prostate cancer patients suffering from bone metastasis, a new treatment offers a significant improvement over traditional pain management.

Physicians at Fengyuan Hospital in Taiwan are now using Radium-223, a radioactive isotope drug, to precisely target bone lesions. This approach has dramatically improved the quality of life for patients like a 50-year-old man who previously endured severe back and pelvic pain, impacting his sleep and mobility.

Prostate cancer is the third most common cancer among Taiwanese men, with over 9,000 new cases annually. As survival rates increase, bone metastasis becomes a critical challenge. The cancer's spread to bones not only destroys tissue but also causes pain, inflammation, and can lead to fractures or spinal cord compression, severely diminishing a patient's quality of life.

Radium-223 works by accumulating in bone metastasis sites, similar to calcium, and releasing short-range alpha rays to attack cancer cells. This targeted therapy can treat multiple bone lesions simultaneously with minimal impact on surrounding healthy tissue. Administered in six sessions every four weeks, most patients can maintain their daily routines during treatment, often avoiding frequent hospitalizations.

While primarily for patients with castration-resistant prostate cancer and symptomatic bone metastasis without visceral organ spread, Radium-223 has demonstrated a survival benefit, extending overall survival from 11.3 to 14.9 months in clinical studies. It also delays skeletal-related events. Physicians advise patients experiencing persistent bone pain, worsening pain relief, or mobility issues to seek prompt medical evaluation.

“

Radium-223 is a radioactive isotope drug specifically targeting bone metastasis lesions.